SCHEMBL14770719

SCHEMBL14770719

CCOc1ccc2[nH]c(C(O)c3ccc(OC)c(Br)c3)nc2c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 3/20 0.48
▸ KMT2A Q03164 3/20 0.48
▸ HTT P42858 2/20 0.48
▸ TOP2A P11388 1/20 0.39
▸ TOP2B Q02880 1/20 0.39
▸ MLKL Q8NB16 2/20 0.38
▸ HIF1A Q16665 1/20 0.38
▸ LMNA P02545 2/20 0.36
▸ HPGD P15428 4/20 0.35
▸ ALDH1A1 P00352 3/20 0.35
▸ MAPT P10636 3/20 0.35
▸ HPSE Q9Y251 1/20 0.35
▸ HSD17B10 Q99714 3/20 0.35
▸ KDM4E B2RXH2 2/20 0.35
▸ SMN1; SMN2 Q16637 2/20 0.35
▸ POLB P06746 1/20 0.34
▸ CFB P00751 1/20 0.34
▸ NPC1 O15118 2/20 0.34
▸ RAB9A P51151 2/20 0.34
▸ ESR2 Q92731 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14770716 0.90 MLKL (0.41) MEN1KMT2AHTTTOP2ATOP2B
SCHEMBL14770655 0.88 MEN1 (0.46) MEN1KMT2AHTTHIF1ALMNA
SCHEMBL12065656 0.88 MEN1 (0.45) MEN1KMT2AHTTMLKLLMNA
SCHEMBL14770471 0.86 MEN1 (0.55) MEN1KMT2AHTTMLKLLMNA
SCHEMBL14770490 0.83 AMY1A (0.43) TOP2ATOP2BMLKLHPSECFB
SCHEMBL14770714 0.81 MLKL (0.59) MEN1KMT2AHTTTOP2ATOP2B
SCHEMBL14763344 0.80 SCN10A (0.39) MEN1KMT2ATOP2ATOP2BMLKL
SCHEMBL14770652 0.78 MEN1 (0.37) MEN1KMT2AHTTLMNAALDH1A1
SCHEMBL12066005 0.78 MEN1 (0.51) MEN1KMT2AHTTTOP2ATOP2B
SCHEMBL12065638 0.77 MEN1 (0.40) MEN1KMT2AHTTMLKLLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096531-B2 Fused imidazole derivative TOA EIYO LTD. (JP) 2015-08-04 — — US disclosed
US-20130065896-A1 FUSED IMIDAZOLE DERIVATIVE TOA EIYO LTD. (JP) 2013-03-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130065896-A1 FUSED IMIDAZOLE DERIVATIVE CACNA1E, CACNA1G, CACNA1A MEN1 2676/4885KMT2A 4545/4885HTT 3959/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback